{
    "clinical_study": {
        "@rank": "106125", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Evaluate the beneficial effects of leuprolide depot, oral contraceptive therapy, and\n      leuprolide/oral contraceptive therapy in the management of patients with ovarian\n      hyperandrogenism."
        }, 
        "brief_title": "Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism", 
        "condition": "Hyperandrogenism", 
        "condition_browse": {
            "mesh_term": "Hyperandrogenism"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized study. Patients are randomly assigned to a 6-month\n      course of leuprolide versus ethinyl estradiol/norethindrone (Ovcon 35) versus leuprolide\n      plus Ovcon 35. Leuprolide is administered intramuscularly in depot form every 28 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        Disease Characteristics\n\n          -  Ovarian hyperandrogenism with Lorenzo hirsutism score 7 to 20, with or without severe\n             acne\n\n          -  Serum hormone levels: Follicle-stimulating hormone no greater than 40 mIU/mL\n             Luteinizing hormone no greater than 40 mIU/mL Testosterone 60 to 200 ng/dL\n             Dehydroepiandrosterone sulfate no greater than 430 micrograms/dL\n             17-hydroxyprogesterone no greater than 3.3 ng/mL in follicular phase Prolactin no\n             greater than 18 ng/dL\n\n          -  No adrenal or ovarian tumors\n\n        Prior/Concurrent Therapy\n\n          -  At least 6 months since exogenous steroids At least 48 hours since drugs other than\n             acetaminophen, ibuprofen, and aspirin\n\n        Patient Characteristics\n\n          -  No malignancy, including the following carcinomas: Breast Cervix Ovary Uterus No\n             other serious illness No cigarette smokers No nursing women No pregnancy within 6\n             months prior to entry"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": "45", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004763", 
            "org_study_id": "199/11717", 
            "secondary_id": "BCM-11717"
        }, 
        "intervention": [
            {
                "intervention_name": "leuprolide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Ethinyl estradiol/norethindrone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptive Agents", 
                "Norethindrone", 
                "Norethindrone acetate", 
                "Norinyl", 
                "Ethynylestradiol mixture with norethindrone", 
                "Contraceptives, Oral", 
                "Estradiol", 
                "Ethinyl Estradiol", 
                "Mestranol", 
                "Leuprolide"
            ]
        }, 
        "keyword": [
            "endocrine disorders", 
            "hyperandrogenism", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Baylor College of Medicine", 
            "last_name": "Karen E. Elkind-Hirsch", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004763"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Baylor College of Medicine", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 1993", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2001"
    }, 
    "geocoordinates": {}
}